Sanger sequencing, also known as chain termination sequencing, refers to a method of DNA sequencing developed by Frederick Sanger in 1977. It helps in determining the precise order of nucleotides in a DNA or RNA strand. Sanger sequencing provides an economical and accurate method of reading long strands of nucleotides, and remains a gold standard technique for targeted small-scale DNA sequencing tasks. It finds wide application in DNA fingerprinting, diagnostic tests, paternity testing, forensic biology, and targeted resequencing studies.
The global Sanger sequencing market is estimated to be valued at US$ 10,130.6 Mn in 2024 and is expected to exhibit a CAGR of 18% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the Global Sanger Sequencing Market are Eurofins Scientific, CeMIA, Fasteris SA, GENEWIZ, GenHunter Corporation, GenScript, LGC Biosearch Technologies, Nucleics, Quintara Biosciences, SciGenom Labs Pvt. Ltd, StarSEQ GmbH, Thermo Fisher Scientific Inc., QIAGEN, Promega Corporation, and Source BioScience. The key opportunities in the market include growing applications of Sanger sequencing in genomics research and clinical diagnostics. Several market players are focusing on geographical expansion strategies through partnerships, collaborations and new laboratory establishments across Asian and African countries to tap potential growth opportunities.
The fastest growing regional market for Sanger sequencing is likely to be Asia Pacific over the forecast period. Rising focus on precision medicine and population genomics-backed initiatives coupled with expanding biotechnology capabilities point towards increasing sequencing demand across China, Japan and India. Strengthening academic and industry collaborations aimed at genomic research and clinical applications are accelerating Asia Pacific growth.
Get more insights on Sanger Sequencing Market
Get more related topic on Sanger Sequencing Market
English
Arabic
Français
Español
Português
Deutsch
Dutch
Italiano
Russian
Romaian